Immediate Impact
1 standout
Citing Papers
Trends in amorphous solid dispersion drug products approved by the U.S. Food and Drug Administration between 2012 and 2023
2024 Standout
Works of Omer Baker being referenced
Elexacaftor, tezacaftor and ivacaftor: a case of severe rash and approach to desensitisation
2022
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Omer Baker | 8 | 1 | 4 | 3 | 11 | 16 | ||
| Daniela Rivero‐Yeverino | 8 | 1 | 1 | 1 | 6 | 11 | 22 | |
| Mehmet Can Aydın | 9 | 12 | 4 | 13 | 17 | |||
| Eugène | 7 | 3 | 4 | 10 | 19 | |||
| Achim Grünewaldt | 6 | 2 | 12 | 15 | ||||
| A. V. Elonakov | 6 | 1 | 2 | 11 | 20 | |||
| L. Guéganton | 12 | 4 | 3 | 1 | 9 | 17 | ||
| E. D. Irvine | 6 | 2 | 2 | 10 | 14 | |||
| Siddhartha Kattamanchi | 6 | 4 | 1 | 2 | 8 | 17 | ||
| Sinan Yavuz | 6 | 4 | 6 | 9 | 16 | |||
| O V Dolzhansky | 4 | 2 | 3 | 10 | 11 |
All Works
Login with ORCID to disown or claim papers
Loading papers...